High-Dose Rosuvastatin Preloading for Enhanced Outcomes in STEMI Patients Undergoing Primary PCI

Phase 2

Active, not recruiting

• Conditions: ST Elevation (STEMI) Myocardial Infarction
• Interventions: Drug: Statin monotherapy (rosuvastatin or atorvastatin); Drug: Placebo

• Registration Number: NCT06924684
• Lead Sponsor: Sheikh Zayed Federal Postgraduate Medical Institute

Brief Summary

To compare the efficacy of high dose rosuvastatin preloading vs placebo before primary PCI in terms of MACE at 30 days

Detailed Description

Not available

Study Timeline

• Status Verified: 2024-12
• Study Start: 2024-12-02
• Study First Submitted: 2024-12-30
• Study First Submitted QC: 2025-04-06
• Last Update Submitted: 2025-04-06
• Study First Posted: 2025-04-11
• Last Update Posted: 2025-04-11
• Primary Completion: 2025-06-23
• Study Completion: 2025-07-02

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 66

Inclusion Criteria

• Age 18-75 years Patients undergoing primary angiography

Exclusion Criteria

• Hemodynamically unstable patients. History or clinical evidence of any co-morbidities. Taking any medications regularly even statins.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Intervention arm	Statin monotherapy (rosuvastatin or atorvastatin)	Tab Rosuvastatin 40mg at presentation. Tab Rosuvastatin 20mg at night for 30 days.
Placebo Arm	Placebo	Placebo capsule 40mg (weight) at presentation. Tab Rosuvastatin 20mg at night for 30 days.

Primary Outcome Measures

Name	Time	Method
In-Hospital mortality	30 days
Incidence of MACE	30 days

Trial Locations

Locations (2)

Shaikh Zayed Hsopital; 🇵🇰 Lahore, Pakistan

Punjab Institute of Cardiology; 🇵🇰 Lahore, Pakistan